卵巢未成熟畸胎瘤的诊治进展

doi:10.12280/gjszjk.20210105

摘要/Abstract

摘要：

卵巢未成熟畸胎瘤是一种好发于育龄妇女的卵巢生殖细胞肿瘤,极易复发及转移,但复发后再次手术可发生恶性程度逆转现象。其来源被认为与减数分裂错误以及表观遗传失调等有关。卵巢未成熟畸胎瘤的症状和体征缺乏特异性。除了传统检查检验手段外,神经元特异性烯醇化酶检验、¹⁸F-氟脱氧葡萄糖（¹⁸F-fluorodeoxyglucose,¹⁸F-FDG）PET/CT等检查方法被认可。由于其在临床相对少见,因此对于成人及儿童患卵巢未成熟畸胎瘤的最佳治疗方案和管理指南目前尚未达成共识,目前主流的治疗方法以手术为主,非必要不进行化疗,并尽量保留患者的生育能力。由于其较易复发,故术后随访极为重要,频率应与其他恶性肿瘤相同。生长性畸胎瘤综合征是卵巢未成熟畸胎瘤的并发症,在临床上较为罕见,手术是其主要治疗手段,同时对其靶向药物治疗的研究也有所进展。综述近年来卵巢未成熟畸胎瘤的来源、诊断、治疗及其并发症的研究进展,以期为临床诊治提供参考。

关键词: 卵巢未成熟畸胎瘤, 畸胎瘤, 卵巢肿瘤, 诊断, 治疗

Abstract:

Immature teratoma of the ovary is a germ cell tumor of the ovary, which is most frequent in women of childbearing age. It is very easy to relapse and metastasize, but the malignant degree can be reversed after recurrence by reoperation. Its origin is thought to be related to meiotic errors and epigenetic disorders. The symptoms and signs of immature teratoma of the ovary are lack of specificity. In addition to the traditional examination methods, neuronspecific enolase test, ¹⁸F-FDG PET/CT and other examination methods have been approved. It is a relatively rare disease, so there is not a clinical guideline for the treatment of ovarian immature teratoma and follow-up management in those adult and child patients. The current mainstream treatment is surgery, not chemotherapy unless it has to be, and to protect the fertility as far as possible. Due to its relatively easy relapse, postoperative follow up is very important. The follow up frequency should be the same as other malignant tumors. Growing teratoma syndrome is a relatively few complication of ovarian immature teratoma. Surgery is the main treatment method for it, and targeted drug therapy also has some progress. The research progress of the source, diagnosis, treatment and complications of ovarian immature teratoma in recent years was reviewed in order to provide a reference for clinical diagnosis and treatment.

Key words: Ovarian immature teratoma, Teratoma, Ovarian Neoplasms, Diagnosis, Therapy

王安生, 杜媛媛, 杨阳. 卵巢未成熟畸胎瘤的诊治进展[J]. 国际生殖健康/计划生育, 2021, 40(6): 524-528.

WANG An-sheng, DU Yuan-yuan, YANG Yang. Progress on Diagnosis and Treatment of Ovarian Immature Teratoma[J]. Journal of International Reproductive Health/Family Planning, 2021, 40(6): 524-528.

参考文献 29

[1]	Dahl N, Gustavson KH, Rune C, et al. Benign ovarian teratomas. An analysis of their cellular origin[J]. Cancer Genet Cytogenet, 1990, 46(1):115-123. doi: 10.1016/0165-4608(90)90017-5. doi: 10.1016/0165-4608(90)90017-5 URL
[2]	Heskett MB, Sanborn JZ, Boniface C, et al. Multiregion exome sequencing of ovarian immature teratomas reveals 2N near-diploid genomes, paucity of somatic mutations, and extensive allelic imbalances shared across mature, immature, and disseminated components[J]. Mod Pathol, 2020, 33(6):1193-1206. doi: 10.1038/s41379-019-0446-y. doi: 10.1038/s41379-019-0446-y URL
[3]	Snir OL, DeJoseph M, Wong S, et al. Frequent homozygosity in both mature and immature ovarian teratomas: a shared genetic basis of tumorigenesis[J]. Mod Pathol, 2017, 30(10):1467-1475. doi: 10.1038/modpathol.2017.66. doi: 10.1038/modpathol.2017.66 URL
[4]	Brind′Amour A, De Guerke L, Fortin S, et al. Recurrent High-grade Ovarian Immature Teratoma with Peritoneal Dissemination[J]. J Pediatr Adolesc Gynecol, 2020, 33(5):586-589. doi: 10.1016/j.jpag.2020.06.002. doi: 10.1016/j.jpag.2020.06.002 URL
[5]	Frazer JL, Hook CE, Addley HC, et al. Recurrent ovarian immature teratoma in a 12-year-old girl: Implications for management[J]. Gynecol Oncol, 2019, 154(2):259-265. doi: 10.1016/j.ygyno.2019.05.032. doi: S0090-8258(19)31277-6 pmid: 31176555
[6]	Abdullahi Idle S, Hayes K, Ross JA. Ultrasound features of immature ovarian teratomas: Case series and review of literature[J]. Ultrasound, 2020, 28(2):82-90. doi: 10.1177/1742271X19895538. doi: 10.1177/1742271X19895538 pmid: 32528544
[7]	闫振宇, 买春阳, 曹学增. 血清肿瘤标志物在卵巢畸胎瘤良恶性鉴别诊断中的价值[J]. 中国妇幼保健, 2016, 31(14):2832-2834. doi: 10.7620/zgfybj.j.issn.1001-4411.2016.14.25. doi: 10.7620/zgfybj.j.issn.1001-4411.2016.14.25
[8]	陈晨, 李俊东, 黄鹤, 等. 肿瘤标志物检测对卵巢成熟、未成熟畸胎瘤的诊断价值[J]. 癌症, 2008, 27(1):92-95. doi: 10.3321/j.issn:1000-467X.2008.01.019. doi: 10.3321/j.issn:1000-467X.2008.01.019
[9]	Wang M, Jiang S, Zhang Y, et al. The application of ¹⁸F-FDG PET/CT in ovarian immature teratomas when pathological examination results contradict clinical observations: a case report[J]. Medicine (Baltimore), 2017, 96(50):e9171. doi: 10.1097/MD.0000000000009171. doi: 10.1097/MD.0000000000009171 URL
[10]	Umehara R, Kurata A, Takanashi M, et al. Fascin as a Useful Marker for Identifying Neural Components in Immature Teratomas of Human Ovary and Those Derived From Murine Embryonic Stem Cells[J]. Int J Gynecol Pathol, 2019, 38(4):377-385. doi: 10.1097/PGP.0000000000000528. doi: 10.1097/PGP.0000000000000528 URL
[11]	李琪, 何南南, 赵曌, 等. 20例卵巢未成熟畸胎瘤临床分析[J]. 肿瘤基础与临床, 2020, 33(3):208-213. doi: 10.3969/j.issn.1673-5412.2020.03.008. doi: 10.3969/j.issn.1673-5412.2020.03.008
[12]	Zhao T, Liu Y, Wang X, et al. Ovarian cystectomy in the treatment of apparent early-stage immature teratoma[J]. J Int Med Res, 2017, 45(2):771-780. doi: 10.1177/0300060517692149. doi: 10.1177/0300060517692149 URL
[13]	金璐, 段振玲, 程大佩, 等. 卵巢肿瘤剥除术在早期卵巢未成熟畸胎瘤中的应用探讨[J]. 医学研究杂志, 2019, 48(10):170-174. doi: 10.11969/j.issn.1673-548X.2019.10.037. doi: 10.11969/j.issn.1673-548X.2019.10.037
[14]	Yu HH, Yonemura Y, Hsieh MC, et al. Experience of applying cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for ovarian teratoma with malignant transformation and peritoneal dissemination[J]. Ther Clin Risk Manag, 2019, 15:129-136. doi: 10.2147/TCRM.S190641. doi: 10.2147/TCRM.S190641 URL
[15]	Wang D, Zhu S, Jia C, et al. Role of staging surgery and adjuvant chemotherapy in adult patients with apparent stage I pure immature ovarian teratoma after fertility-sparing surgery[J]. Int J Gynecol Cancer, 2020, 30(5):664-669. doi: 10.1136/ijgc-2019-001116. doi: 10.1136/ijgc-2019-001116 pmid: 32179695
[16]	Imran H, Siddiqui AH, Wilson F, et al. Growing Teratoma Syndrome After Chemotherapy For Ovarian Immature Teratoma[J]. J Pediatr Hematol Oncol, 2020, 42(7):e630-e633. doi: 10.1097/MPH.0000000000001525. doi: 10.1097/MPH.0000000000001525 URL
[17]	姚迎春, 王玲, 韩丽英. 卵巢生长性畸胎瘤综合征一例并文献复习[J]. 国际生殖健康/计划生育杂志, 2019, 38(6):483-485.
[18]	Tullius BP, Shankar SP, Cole S, et al. Novel heterozygous mutation in the PTEN gene associated with ovarian germ cell tumor complicated by growing teratoma syndrome and overgrowth in a two-year-old female[J]. Pediatr Blood Cancer, 2019, 66(8):e27788. doi: 10.1002/pbc.27788. doi: 10.1002/pbc.27788
[19]	Wang D, Zhu S, Jia C, et al. Diagnosis and management of growing teratoma syndrome after ovarian immature teratoma: A single center experience[J]. Gynecol Oncol, 2020, 157(1):94-100. doi: 10.1016/j.ygyno.2019.12.042. doi: S0090-8258(19)31872-4 pmid: 31954532
[20]	Van Nguyen JM, Bouchard-Fortier G, Ferguson SE, et al. How Common Is the Growing Teratoma Syndrome in Patients With Ovarian Immature Teratoma?[J]. Int J Gynecol Cancer, 2016, 26(7):1201-1206. doi: 10.1097/IGC.0000000000000751. doi: 10.1097/IGC.0000000000000751 pmid: 27258729
[21]	Vaughn DJ, Flaherty K, Lal P, et al. Treatment of growing teratoma syndrome[J]. N Engl J Med, 2009, 360(4):423-424. doi: 10.1056/NEJMc0808558. doi: 10.1056/NEJMc0808558 URL
[22]	Narayan V, Hwang WT, Lal P, et al. Cyclin-Dependent Kinase 4/6 Inhibition for the Treatment of Unresectable Mature Teratoma: Long-Term Follow-Up of a Phase II Study[J]. Clin Genitourin Cancer, 2016, 14(6):504-510. doi: 10.1016/j.clgc.2016.03.010. doi: 10.1016/j.clgc.2016.03.010 URL
[23]	Shinkai T, Masumoto K, Chiba F, et al. Pediatric ovarian immature teratoma: Histological grading and clinical characteristics[J]. J Pediatr Surg, 2020, 55(4):707-710. doi: 10.1016/j.jpedsurg.2019.04.037. doi: S0022-3468(19)30348-3 pmid: 31130350
[24]	Faure-Conter C, Pashankar F. Immature Ovarian Teratoma: When to Give Adjuvant Therapy?[J]. J Pediatr Hematol Oncol, 2017, 39(7):487-489. doi: 10.1097/MPH.0000000000000950. doi: 10.1097/MPH.0000000000000950 URL
[25]	Pashankar F, Hale JP, Dang H, et al. Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative[J]. Cancer, 2016, 122(2):230-237. doi: 10.1002/cncr.29732. doi: 10.1002/cncr.29732 pmid: 26485622
[26]	Ye CJ, Zhan Y, Yang R, et al. Single-cell transcriptional profiling identifies a cluster of potential metastasis-associated UBE2C+ cells in immature ovarian teratoma[J]. Biochem Biophys Res Commun, 2020, 528(3):567-573. doi: 10.1016/j.bbrc.2020.05.144. doi: 10.1016/j.bbrc.2020.05.144 URL
[27]	Chan JK, Gardner AB, Chan JE, et al. The influence of age and other prognostic factors associated with survival of ovarian immature teratoma - A study of 1307 patients[J]. Gynecol Oncol, 2016, 142(3):446-451. doi: 10.1016/j.ygyno.2016.07.001. doi: 10.1016/j.ygyno.2016.07.001 URL
[28]	Jorge S, Jones NL, Chen L, et al. Characteristics, treatment and outcomes of women with immature ovarian teratoma, 1998-2012[J]. Gynecol Oncol, 2016, 142(2):261-266. doi: 10.1016/j.ygyno.2016.05.024. doi: 10.1016/j.ygyno.2016.05.024 URL
[29]	郝丽军, 秦秀荣, 张新, 等. 卵巢恶性畸胎瘤临床预后分析[J]. 中国实用妇科与产科杂志, 2005, 21(7):432-433. doi: 10.3969/j.issn.1005-2216.2005.07.022. doi: 10.3969/j.issn.1005-2216.2005.07.022